FGFR2 and endometrial cancer: Given that dovitinib may exert its anticancer effects either by directly targeting FGFRs or regulators of angiogenesis, endometrial cancer patients with or without FGFR2 mutations are separately enrolled in a clinical to prove its mechanisms of functions [166].